Drug Type CRISPR/Cas |
Synonyms β-globin restored autologous hematopoietic stem cells(Shenzhen Hemogen), 编码T87Q倍他珠蛋白慢病毒转导的自体造血干祖细胞(禾沐基因) + [2] |
Target |
Mechanism β-globin modulators(Hemoglobin beta chain modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Transfusion-dependent Beta Thalassemia | Phase 2 | - | - | |
Beta-Thalassemia | Phase 1 | CN | 01 Dec 2020 |